Accumulating evidence suggests that a high tumour burden has a negative effect on
anticancer immunity. The concept of tumour burden, simply defined as the total amount of …

Abstract Treatment with immune checkpoint inhibitors (ICI) has demonstrated clinical benefit
for a wide range of cancer types. Because only a subset of patients experience clinical …

Immunotherapy has become the standard-of-care in many solid tumors. Despite the
significant recent achievements in the diagnosis and treatment of cancer, several issues …

Background Immune checkpoint inhibitors have revolutionized cancer therapeutic paradigm
and substantially improved the survival of patients with advanced malignancies. However, a …

Immune-checkpoint inhibitors have revolutionized cancer therapy, yet many patients either
do not derive any benefit from treatment or develop a resistance to checkpoint inhibitors …

Simple Summary Immune checkpoint inhibitors (ICIs) are the most mature treatment of
immunotherapy and have changed the mode of cancer treatment. Recent studies showed …

Background Recently, immune-checkpoint blockade has shown striking clinical results in
different cancer patients. However, a significant inter-individual and inter-tumor variability …

As cancer immunotherapy using immune checkpoint inhibitors (ICIs) is rapidly evolving in
clinical practice, it is necessary to identify biomarkers that will allow the selection of cancer …

Considerable interest surrounds the use of immune-checkpoint inhibitors in patients with
solid tumours following the demonstration of the impressive clinical efficacy of anti …

Introduction Systemic inflammation is associated with prognosis in solid tumors. The
neutrophil-to-lymphocyte ratio (NLR) is a marker for the general immune response to various …